Cargando…
CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma
Glioblastoma (GBM) is a lethal brain tumour. Despite therapy with surgery, radiation, and alkylating chemotherapy, most people have recurrence within 6 months and die within 2 years. A major reason for recurrence is resistance to DNA damage. Here, we demonstrate that CHD4, an ATPase and member of th...
Autores principales: | McKenzie, Lisa D., LeClair, John W., Miller, Kayla N., Strong, Averey D., Chan, Hilda L., Oates, Edward L., Ligon, Keith L., Brennan, Cameron W., Chheda, Milan G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418088/ https://www.ncbi.nlm.nih.gov/pubmed/30872624 http://dx.doi.org/10.1038/s41598-019-40327-w |
Ejemplares similares
-
Regulation and pharmacological targeting of RAD51 in cancer
por: Grundy, McKenzie K, et al.
Publicado: (2020) -
Cannabidiol inhibits RAD51 and sensitizes glioblastoma to temozolomide in multiple orthotopic tumor models
por: Soroceanu, Liliana, et al.
Publicado: (2022) -
Roles of XRCC2, RAD51B and RAD51D in RAD51-Independent SSA Recombination
por: Serra, Heïdi, et al.
Publicado: (2013) -
Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor
por: Greenhough, Luke A., et al.
Publicado: (2023) -
Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients
por: Morrison, Christopher, et al.
Publicado: (2021)